Log in

NASDAQ:MBII - Marrone Bio Innovations Stock Price, Forecast & News

0.00 (0.00 %)
(As of 02/28/2020 06:54 AM ET)
Today's Range
Now: $1.14
50-Day Range
MA: $1.17
52-Week Range
Now: $1.14
Volume108,283 shs
Average Volume130,076 shs
Market Capitalization$152.08 million
P/E RatioN/A
Dividend YieldN/A
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. Read More…

Industry, Sector and Symbol

Industry Agricultural chemicals
SectorBasic Materials
Current SymbolNASDAQ:MBII



Sales & Book Value

Annual Sales$21.22 million
Book Value$0.12 per share


Net Income$-20,210,000.00
Net Margins-123.42%


Market Cap$152.08 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive MBII News and Ratings via Email

Sign-up to receive the latest news and ratings for MBII and its competitors with MarketBeat's FREE daily newsletter.

Marrone Bio Innovations (NASDAQ:MBII) Frequently Asked Questions

What is Marrone Bio Innovations' stock symbol?

Marrone Bio Innovations trades on the NASDAQ under the ticker symbol "MBII."

How were Marrone Bio Innovations' earnings last quarter?

Marrone Bio Innovations Inc (NASDAQ:MBII) issued its earnings results on Thursday, August, 8th. The basic materials company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The basic materials company earned $7 million during the quarter, compared to analyst estimates of $9.01 million. Marrone Bio Innovations had a negative return on equity of 180.33% and a negative net margin of 123.42%. View Marrone Bio Innovations' Earnings History.

When is Marrone Bio Innovations' next earnings date?

Marrone Bio Innovations is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Marrone Bio Innovations.

What price target have analysts set for MBII?

3 analysts have issued 1 year price targets for Marrone Bio Innovations' stock. Their forecasts range from $2.00 to $2.50. On average, they expect Marrone Bio Innovations' share price to reach $2.33 in the next year. This suggests a possible upside of 104.7% from the stock's current price. View Analyst Price Targets for Marrone Bio Innovations.

What is the consensus analysts' recommendation for Marrone Bio Innovations?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marrone Bio Innovations in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marrone Bio Innovations.

What are Wall Street analysts saying about Marrone Bio Innovations stock?

Here are some recent quotes from research analysts about Marrone Bio Innovations stock:
  • 1. HC Wainwright analysts commented, "We have not yet incorporated the effect of the financing and the proposed acquisition in our model. If, and when, the transaction closes, we believe that the company’s revenues for 2019 should be expected to be higher, relative to our current expectation, by single-digit millions. Currently, we are projecting MBII to generate revenues of $30.3M in 2019. We expect revenues to reach $160.7M in 2025, growing at a six-year CAGR of 32.0%, relative to 2019 levels. We are estimating gross margin to stay at 55-56% level for the next several years." (8/12/2019)
  • 2. National Securities analysts commented, "Second Quarter Results. Revenue of $7.0 million grew 22% YoY but missed consensus estimates of $8.3 million, while gross margins improved and adjusted operating expenses remained roughly flat sequentially. Overall, the second quarter continued the trend of directional improvement, but the scale of the improvement was a modest disappointment to us especially when considering what were favorable comps off of a weak second quarter of 2018.
     Acquisition Of Pro Farm The Highlight. Most significantly, MBII announced its acquisition of a biostimulant peer Pro Farm Technologies for $31.8 million. The acquisition expands MBII’s presence in the high growth seed treatment market and diversifies its product offering away from biopesticides with a second biostimulant offering.
     Supportive Of The Transaction. We are bullish on the seed treatment market over both the near and long term and believe additional exposure can create meaningful shareholder value. Furthermore, given our estimates for the financial impact, the acquisition enhances our belief that MBII will pivot to cash flow breakeven in 2021. We had previously modeled MBII to operate at Adjusted EBITDA breakeven in 2021. With the transaction, we look for 2021 to now generate a modest EBITDA profit.
     Long Term Value Creation. With the integration of Pro Farms and collaborations with other commercial partners, MBII is targeting a more diverse product portfolio that broadens its biological offerings beyond biopesticides to include biostimulants and biofertilizers. Should scale develop as we believe it can over the mid-term, we believe MBII will look increasingly attractive to larger peers which may generate meaningful value for long term shareholders." (8/9/2019)
  • 3. Aegis analysts commented, "We think Marrone Bio has a scalable, repeatable business model. We think Marrone Bio’s roots are in innovation, with an organization that is heavy on research talent, with a tenured management team of industry veterans. In recent years, Marrone’s focus has been on commercializing this R&D investment, and the company has a portfolio of commercial products on the market. Marrone Bio’s model consists of discovering novel bio-based compounds, refining them with in-house expertise and laboratory equipment, and introducing them to the commercial sphere. We think Marrone can continue to execute on this strategy as it moves increasingly close to profitability." (7/24/2019)

Has Marrone Bio Innovations been receiving favorable news coverage?

News stories about MBII stock have been trending extremely negative on Friday, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Marrone Bio Innovations earned a daily sentiment score of -4.2 on InfoTrie's scale. They also assigned headlines about the basic materials company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Marrone Bio Innovations.

Are investors shorting Marrone Bio Innovations?

Marrone Bio Innovations saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,860,000 shares, an increase of 11.3% from the January 15th total of 2,570,000 shares. Based on an average daily trading volume, of 139,600 shares, the days-to-cover ratio is presently 20.5 days. Currently, 3.5% of the shares of the stock are short sold. View Marrone Bio Innovations' Current Options Chain.

Who are some of Marrone Bio Innovations' key competitors?

What other stocks do shareholders of Marrone Bio Innovations own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marrone Bio Innovations investors own include Rexahn Pharmaceuticals (REXN), Denali Therapeutics (DNLI), Canopy Growth (CGC), Yield10 Bioscience (YTEN), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON), Ekso Bionics (EKSO), Micron Technology (MU), Tilray (TLRY) and 22nd Century Group (XXII).

Who are Marrone Bio Innovations' key executives?

Marrone Bio Innovations' management team includes the folowing people:
  • Dr. Pamela G. Marrone, Founder, CEO & Director (Age 62)
  • Mr. James B. Boyd, Pres & CFO (Age 66)
  • Ms. Linda V. Moore, Chief Compliance Officer, Gen. Counsel, Exec. VP & Sec. (Age 72)
  • Dr. Amit Vasavada Ph.D., Sr. VP of R&D and CTO (Age 64)
  • Andre Trepanier, Director of Marketing

Who are Marrone Bio Innovations' major shareholders?

Marrone Bio Innovations' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.61%), Geode Capital Management LLC (0.40%), Essex Investment Management Co. LLC (0.40%), Goldman Sachs Group Inc. (0.11%), UBS Group AG (0.06%) and Barclays PLC (0.04%). Company insiders that own Marrone Bio Innovations stock include Ardsley Advisory Partners and Van Herk Investments BV. View Institutional Ownership Trends for Marrone Bio Innovations.

Which major investors are selling Marrone Bio Innovations stock?

MBII stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for Marrone Bio Innovations.

Which major investors are buying Marrone Bio Innovations stock?

MBII stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Barclays PLC, Essex Investment Management Co. LLC and Geode Capital Management LLC. View Insider Buying and Selling for Marrone Bio Innovations.

How do I buy shares of Marrone Bio Innovations?

Shares of MBII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Marrone Bio Innovations' stock price today?

One share of MBII stock can currently be purchased for approximately $1.14.

How big of a company is Marrone Bio Innovations?

Marrone Bio Innovations has a market capitalization of $152.08 million and generates $21.22 million in revenue each year. The basic materials company earns $-20,210,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Marrone Bio Innovations employs 113 workers across the globe.View Additional Information About Marrone Bio Innovations.

What is Marrone Bio Innovations' official website?

The official website for Marrone Bio Innovations is http://www.marronebioinnovations.com/.

How can I contact Marrone Bio Innovations?

Marrone Bio Innovations' mailing address is 1540 Drew Avenue, Davis CA, 95618. The basic materials company can be reached via phone at 530-750-2800 or via email at [email protected]

MarketBeat Community Rating for Marrone Bio Innovations (NASDAQ MBII)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  210 (Thanks for Voting!)
Underperform Votes:  255 (Thanks for Voting!)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about Marrone Bio Innovations and other stocks. Vote "Outperform" if you believe MBII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Price-Sales Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel